Preclinical

We are Scientists and Innovators

We accelerate drug discovery through unparalleled preclinical evaluation of novel therapeutics in our advanced genetically engineered in vivo models. With cutting-edge gene editing and RNA interference technologies, we are leaders in developing human models of disease. Our experience, capabilities, and agility help our partners achieve velocity to critical decisions for their therapies.

Oncology

Cardiovascular & Metabolic

Genetic Rare Diseases

Immunology & Inflammation

In Vitro / Ex Vivo Cell-Based Studies

Cell Line & Organoid Model Creation
Custom Assay Design & Optimization
Gene Editing for Gene KIs, KOs, & Point Mutations
Reporter Cell Lines

In Vivo Studies

Orthotopic Transplant Models
Xenograft Models
Preclinical Evaluation
- Tumor volume measurements
- Biomarker identification
- Transcriptomics
- Proteomics

Drug Testing
- Toxicology
- PK/PD
- Efficacy/Safety
Advanced Imaging & Analysis
Pathology & Necropsy

Custom Animal Model Creation

Mirimus averages cutting-edge technology to rapidly create customized genetically engineered mouse and rat models for preclinical research.

A flowchart depicting the stages of a project, from initiation to completion. The stages are listed as: project initiation and design, vector design, ESC targeting and founder animals validation. Each stage is estimated to take one month, except for ESC targeting and founder animals validation, which is estimated to take two months. There is a total project timeline of five to six months.

Gene deletion
Conditional knock-out
Point mutations
Site-specific transgene knock-in
Reporter models
Cre models
Tet-transactivator models
Humanized models
Inducible RNAi models
Rare disease models
Cancer models
- Syngeneic models
- Orthotopic models
- PDX models

RNAi Models with Inducible Gene Silencing

Mirimus revolutionizes preclinical research by harnessing the power of RNA interference (RNAi). Our mouse and rat models provide a unique platform to mimic drug therapy with inducible, reversible, and dose-dependent gene silencing to validate novel drug targets in vivo with high predictive power.

Mice, rats, and embryonic stem cells

Inducible, reversible, and dose-
dependent gene silencing

Proprietary miRNA expression cassettes

Turnaround time < 6 months

RNAi models can be used to validate candidate gene targets by:

Assessing therapeutic effects of gene silencing
Assessing the potential toxicity associated with gene silencing

OPTIMUS In Vivo Reporter System

One major challenge in RNAi therapeutics is identifying delivery strategies that can be translated to the clinic.
Our proprietary in vivo reporter mouse model for screening and optimization of oligonucleotide therapeutics.
Assess unique delivery vehicles coupled to oligonucleotide payloads to develop the best-in-class new molecular entities.

Preclinical Services

Your New Partner in Drug Discovery